TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03814486

Intervention type: OTHER
Intervention: descriptive
Description: evaluate in number and efficacy platelet transfusion at the end of life, demographic characteristic are also noted
Study: NCT04331795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Group A: Tocilizumab (beginning dose 200mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.~Second dose is provisioned if:~1. Increasing supplemental oxygen requirement or Tmax higher than baseline in the 24h following initial tocilizumab administration AND~2. CRP decrease is \< 25% at 24 hours following tocilizumab administration and CRP \> 40mg/L

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Group B: Low-dose tocilizumab (beginning dose 80mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.~Second dose is provisioned if:~1. Increasing supplemental oxygen requirement or Tmax higher than baseline in the 24h following initial tocilizumab administration AND~2. CRP decrease is \< 25% at 24 hours following tocilizumab administration and CRP \> 40mg/L
Study: NCT02396134

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMVpp65-A*0201 peptide vaccine
Description: Given SC

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02094456

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic clipping of diverticula
Description: Colonoscopy with identification of each individual colonic diverticula and endoscopic clipping.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Follow-up colonoscopy
Description: Patients will undergo a repeat colonoscopy 6 months after endoscopic clipping procedure.
Study: NCT02483663

Intervention type: DEVICE
Intervention: Functional Magnetic Resonance Imaging
Description: Measure brain activity.

Intervention type: DEVICE
Intervention: Functional Magnetic Resonance Imaging
Description: Measure brain activity.

Intervention type: RADIATION
Intervention: Dual Energy X-ray absorptiometry
Description: Body composition measurements.

Intervention type: RADIATION
Intervention: Dual Energy X-ray absorptiometry
Description: Body composition measurements.

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires related to: health, weight, sleep, mood, dietary habits, attitudes towards eating, how you describe yourself.

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires related to: health, weight, sleep, mood, dietary habits, attitudes towards eating, how you describe yourself.

Intervention type: OTHER
Intervention: Mood and Appetite Ratings
Description: Answer questions about how you are feeling at the moment.

Intervention type: OTHER
Intervention: Mood and Appetite Ratings
Description: Answer questions about how you are feeling at the moment.

Intervention type: OTHER
Intervention: Test Meals
Description: Breakfast, a snack, and lunch provided during study visit.

Intervention type: OTHER
Intervention: Test Meals
Description: Breakfast, a snack, and lunch provided during study visit.

Intervention type: OTHER
Intervention: Computer Tests
Description: Perform a series of computer tests to determine reaction time.

Intervention type: OTHER
Intervention: Computer Tests
Description: Perform a series of computer tests to determine reaction time.

Intervention type: PROCEDURE
Intervention: Intravenous Catheter (IV) placement
Description: Blood samples collected throughout regular intervals during the study visit day to measure levels of hormones involved in regulating appetite and body weight. We will also determine if twins are fraternal or identical and will examine DNA to see if participants carry two genes that affect appetite or body weight, the FTO gene and the MC4R gene.

Intervention type: PROCEDURE
Intervention: Intravenous Catheter (IV) placement
Description: Blood samples collected throughout regular intervals during the study visit day to measure levels of hormones involved in regulating appetite and body weight. We will also determine if twins are fraternal or identical and will examine DNA to see if participants carry two genes that affect appetite or body weight, the FTO gene and the MC4R gene.
Study: NCT04075474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: silver diamine fluoride
Description: 38% SDF on primary upper anterior teeth

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sodium fluoride
Description: 5% NaF on primary upper anterior teeth
Study: NCT02192203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac + Menthol Gel
Description: 1% diclofenac, 3% menthol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Only Gel
Description: 1% diclofenac, 0.09% menthol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menthol Only Gel
Description: 3% menthol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Only Gel
Description: 0.09% menthol
Study: NCT04032600

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Paracentesis
Description: Full versus partial paracentesis (3 liters)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Paracentesis
Description: Full versus partial paracentesis (3 liters)
Study: NCT01709149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-2017357
Description: CK-2017357 125 mg tablets twice daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riluzole
Description: Tablets
Study: NCT03201458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT00576459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.59 mg fluocinolone acetonide intravitreal implant
Description: 0.59 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.1 mg fluocinolone acetonide intravitreal implant
Description: 2.1 mg

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard of care laser photocoagulation
Description: standard of care laser photocoagulation
Study: NCT04352959

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mouthrinse with bêta-cyclodextrin and citrox
Description: 3 daily mouthrinses for 7 days

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: mouthrinse without bêta-cyclodextrin and citrox
Description: 3 daily mouthrinses for 7 days
Study: NCT03076203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given orally

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radium Ra 223 Dichloride
Description: Given intravenously
Study: NCT00930761

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Music therapy sessions systematically offered to all mothers in the intervention group, three times a week, not mandatory, conducted by two music therapists in an appropriate room, during 60 minutes.
Study: NCT01263821

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted magnetic resonance imaging
Description: Undergo diffusion-weighted MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perfusion-weighted magnetic resonance imaging
Description: Undergo perfusion-weighted magnetic resonance imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging
Description: Undergo functional MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance spectroscopic imaging
Description: Undergo MR spectroscopic imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic conventional surgery
Description: Undergo maximal surgical resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation therapy treatment planning/simulation
Description: Undergo IMRT planning

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy
Description: Undergo intensity-modulated radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Description: Ancillary studies
Study: NCT03959332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baloxavir Marboxil
Description: Participants will receive either 40 mg or 80 mg of baloxavir marboxil on Day 1 as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baloxavir Marboxil
Description: Participants will receive either 40 mg or 80 mg of baloxavir marboxil on Day 1 as a single oral dose.
Study: NCT01826253

Intervention type: DRUG
Intervention: hydroxyethylstarch 130/0.4
Description: Bolus of 100ml of HES 130/0.4 repeated until maximization of cardiac output
Study: NCT00397813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo transplantation
Study: NCT03848026

Intervention type: OTHER
Intervention: Middle ear fluid viscosity
Description: The patients were subdivided into two groups according to median viscosity level

Intervention type: OTHER
Intervention: Middle ear fluid viscosity
Description: The patients were subdivided into two groups according to median viscosity level
Study: NCT00397813

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSC transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSC transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSC transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSC transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSC transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSC transplant

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study: NCT02069405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation Music
Study: NCT03007056

Intervention type: OTHER
Intervention: High flow nasal cannula
Description: High flow nasal cannula added to the therapeutic arsenal in neonatal care
Study: NCT02854423

Intervention type: DEVICE
Intervention: percutaneous coronary interventions
Description: Consecutive diabetic patients undergoing percutaneous coronary interventions with Biodegradable polymer Biolimus Eluting Stent or durable polymer Everolimus Eluting Stent implantation

Intervention type: DEVICE
Intervention: percutaneous coronary interventions
Description: Consecutive diabetic patients undergoing percutaneous coronary interventions with Biodegradable polymer Biolimus Eluting Stent or durable polymer Everolimus Eluting Stent implantation
Study: NCT02120014

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood volume measurement
Description: Patients will drink a solution 30 minutes prior to the test. They will need to lie still on a flat surface for 15 minutes. During the blood volume analysis portion of the test, a small amount of a radioactive isotope or tracer is injected.Blood samples are taken at 6 time points during the test. The blood volume test is used to measure the amount of blood in the patients body.~A hematocrit measurement is done on the blood samples taken. This blood test calculates the percentage of red blood cells in the bloodstream.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood volume measurement
Description: Patients will drink a solution 30 minutes prior to the test. They will need to lie still on a flat surface for 15 minutes. During the blood volume analysis portion of the test, a small amount of a radioactive isotope or tracer is injected.Blood samples are taken at 6 time points during the test. The blood volume test is used to measure the amount of blood in the patients body.~A hematocrit measurement is done on the blood samples taken. This blood test calculates the percentage of red blood cells in the bloodstream.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: venous plethysmography
Description: venous plethysmography is a non-invasive test to measure how well your veins and arteries in your forearm and calf work. Cuffs similar to blood pressure cuffs are placed on the upper and lower arm and the thigh and calf. Measurements are taken

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: venous plethysmography
Description: venous plethysmography is a non-invasive test to measure how well your veins and arteries in your forearm and calf work. Cuffs similar to blood pressure cuffs are placed on the upper and lower arm and the thigh and calf. Measurements are taken
Study: NCT01157364

Intervention type: DRUG
Group type: OTHER
Intervention: bimatoprost 20 µg generation 2
Description: Single dose of bimatoprost ophthalmic administered in the study eye on Day 1.

Intervention type: DRUG
Group type: OTHER
Intervention: bimatoprost 15 µg generation 2
Description: Single dose of bimatoprost ophthalmic administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).

Intervention type: DRUG
Group type: OTHER
Intervention: bimatoprost 10 µg generation 2
Description: Single dose of bimatoprost ophthalmic 10 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).

Intervention type: DRUG
Group type: OTHER
Intervention: bimatoprost 6 µg generation 2
Description: Single dose of bimatoprost ophthalmic 6 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).

Intervention type: DRUG
Group type: OTHER
Intervention: bimatoprost 15 µg generation 1
Description: Single dose of bimatoprost ophthalmic 15 µg generation 1 administered in the study eye on Day 1.

Intervention type: DRUG
Group type: OTHER
Intervention: bimatoprost 10 µg generation 1
Description: Single dose of bimatoprost ophthalmic 10 µg generation 1 administered in the study eye on Day 1.
Study: NCT03848026

Intervention type: OTHER
Intervention: Tympanostomy tube extrusion time
Description: Tympanostomy tube extrusion time of the all patients recorded prospectively.

Intervention type: OTHER
Intervention: Tympanostomy tube extrusion time
Description: Tympanostomy tube extrusion time of the all patients recorded prospectively.
Study: NCT01157364

Intervention type: DRUG
Group type: OTHER
Intervention: bimatoprost 0.03%
Description: One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.

Intervention type: DRUG
Group type: OTHER
Intervention: bimatoprost 0.03%
Description: One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.

Intervention type: DRUG
Group type: OTHER
Intervention: bimatoprost 0.03%
Description: One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.

Intervention type: DRUG
Group type: OTHER
Intervention: bimatoprost 0.03%
Description: One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.

Intervention type: DRUG
Group type: OTHER
Intervention: bimatoprost 0.03%
Description: One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.

Intervention type: DRUG
Group type: OTHER
Intervention: bimatoprost 0.03%
Description: One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
Study: NCT03991130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2 and Nivolumab
Description: Course length will be 35 days. Subjects will receive 480 mg IV of nivolumab on day 1 of the cycle. The patient will be admitted to UCSD Jacobs Medical center for standard HD IL-2 which will be administered every 8 hrs for up to 14 doses days 8-12 per institutional practice. The patient will be readmitted days 22-28 for HD IL-2 every 8 hrs for up to 14 doses. Nivolumab 480 mg IV will be administered day 35. Scans for response will occur 4 weeks after day 35 nivolumab dose and response will be determined by RECIST 1.1 to determine if the patient will receive the next course.
Study: NCT04191382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amcenestrant (SAR439859)
Description: Pharmaceutical form: Capsules, Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amcenestrant (SAR439859)
Description: Pharmaceutical form: Capsules, Route of administration: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Pharmaceutical form: Tablets, Route of administration: Oral
Study: NCT01717209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: inhaled nitric oxide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prostacyclin
Description: inhaled prostacyclin
Study: NCT04085679

Intervention type: OTHER
Intervention: Multidisciplinary Mobile Unit (MMU)
Description: MMU is called in case of urgent clinical situations involving patients residing in nursing home